Marketing and Manufacturing of Pharmaceuticals


ReqMed received approval to manufacture and market Cystadan® bulk powder in Japan on January 17, 2014, for the treatment of (to treat) homocystinuria, and started sales on May 27, 2014. The manufacturing and marketing approval has been transferred to Recordati Rare Diseases Japan K.K. as of January 1, 2022.